InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
2
Disclosed sells
0
T+90 hit rate
40%
T+90 mean return
-7.0%
Across 15 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Serbousek Jon Carl, Chairman & CEO. Insider active across 1 company, notably Orthofix Medical Inc.. Cumulatively, 15 disclosures have been logged. Breakdown: 2 buys · 0 sell. Total volume traded: €92k. Activity tracked since 5 August 2021. The latest transaction was filed on 3 April 2023 (Retenue fiscale). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations15 total
6,141 shares@ US$16.7513.1% of flowCommon StockSEC:0001209191-23-023445:0
5,142 shares@ US$21.5414.2% of flowCommon StockSEC:0001209191-23-007203:0
45,872 shares0Common StockSEC:0001209191-23-002660:0
45,872 shares0Common StockSEC:0001209191-23-002662:0
2,369 shares@ US$16.215.4% of flowCommon StockSEC:0001209191-22-055521:0
1,450 shares@ US$22.774.5% of flowCommon StockSEC:0001209191-22-045058:0
3,899 shares@ US$33.040.019% mcap25.7% of flowCommon StockSEC:0001209191-22-023339:0
81,967 shares0Common StockSEC:0001209191-22-006835
81,967 shares0Common StockSEC:0001209191-22-006835:0
1,670 shares@ US$31.146.4% of flowCommon StockSEC:0001209191-21-065552
Canonical exit: 16 Feb 2022 (T+90)
1,670 shares@ US$31.140.0076% mcap10.2% of flowCommon StockSEC:0001209191-21-065552:0
Canonical exit: 16 Feb 2022 (T+90)
2,369 shares@ US$36.870.013% mcap16.7% of flowCommon StockSEC:0001209191-21-062275:0
2,369 shares@ US$36.8710.5% of flowCommon StockSEC:0001209191-21-062275
1,450 shares@ US$37.980.0077% mcap10.3% of flowCommon StockSEC:0001209191-21-050298:0
1,450 shares@ US$37.986.5% of flowCommon StockSEC:0001209191-21-050298
15 of 15 declarations
About Serbousek Jon Carl
Jon Carl Serbousek is the CEO of Orthofix Medical Inc. He leads the company with a vision focused on innovation in the medical device field. His leadership is crucial for Orthofix's growth, ensuring that the company remains at the forefront of technological advancements.
